Tropical Journal of Pharmaceutical Research

Case Report | OPEN ACCESS

Long response to camrelizumab in metastatic lung squamous cell carcinoma with high PD-L1 expression despite EGFR G719S mutation: A case report

Yuhua Wang, Ke Fang

Department of Oncology, Gaoxin Hospital of the First Affiliated Hospital of Nanchang University, 7889 Changdong Avenue, Nanchang City, Jiangxi Province, China;

For correspondence:- Ke Fang Email: fangkeqq88@163.com

Accepted: 22 June 2023 Published: 31 July 2023

Citation: Wang Y, Fang K. Long response to camrelizumab in metastatic lung squamous cell carcinoma with high PD-L1 expression despite EGFR G719S mutation: A case report. Trop J Pharm Res 2023; 22(7):1525-1529 doi: 10.4314/tjpr.v22i7.24

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Immune checkpoint inhibitors (ICIs) have been widely used in non-small cell lung cancer with wildtype EGFR/ALK genes. However, the effect of ICIs on advanced NSCLC with EGFR genes sensitive mutations has been controversial. There are no reports on whether ICIs monotherapy can be used in the treatment of NSCLC with EGFR sensitive mutations. A patient with metastatic lung squamous cell carcinoma with EGFR G719s mutations, high PD-L1 score and a tuberculosis history was given first-line treatment of afatinib, camrelizumab monotherapy (200 mg, intravenous, once every three weeks) from February 24,2020 to January 2023. The patient achieved partial response (PR) after treatment with camrelizumab. The progress-free survival (PFS) due to camrelizumab monotherapy was more than 34 months.It is concluded that camrelizumab has promising potential effectiveness as a treatment option for lung squamous cell cancer with EGFR G719 mutations and high PD-L1 score.

Keywords: Prolonged response, Immuno-checkpoint suppressor, Lung cancer; EGFR mutation, Progress-free survival, Camrelizumab, Afatinib